8 Hours of Sleep and Still Tired? Start-Up Sleepiz and LuftiBus Can Help You Understand Why.
ZÜRICH – Sleepiz AG announces a partnership with LUNGE ZÜRICH. After a successful pilot, LUNGE ZÜRICH will include the Sleepiz One, Switzerland’s first contactless screening, to its LuftiBus offering.
More than 150 000 people in Switzerland sleep for 8 hours every night but still feel tired, drained, or irritable in the morning. These people suffer from sleep apnea, a disease where a person stops breathing for at least 15 times an hour during their sleep, often accompanied by loud snoring. Untreated sleep apnea increases the risk of high blood pressure, obesity, heart disease, and depression. It can also lead to a loss of productivity and significant increase in the risk of work or car accidents. Yet only about 20% of the people affected are diagnosed.
Through LUNGE ZÜRICH’s LuftiBus, companies can now book a contactless sleep screening with Sleepiz One for their employees. Sleepiz One device will be directly sent to their home, where they will sleep with it for 3 nights. After the sleep screening, trained LuftiBus staff will consult and discuss the results with each employee. The consultation will tell whether the person is at risk of sleep apnea or if there are any abnormalities. Tips on sleep hygiene from the LuftiBus team will also be shared to help everyone sleep better.
The offer is available to all interested companies or associations with a minimum of 10 employees. For detailed information and prices, please contact LUNGE ZÜRICH directly.
Why a Sleep Screening with Sleepiz One?
The diagnosis of sleep apnea is an uncomfortable, costly, and time-consuming procedure. Today, patients either have to go to a sleep lab, where they spend the night with more than 30 sensors on their bodies, or they are given a device to take home and have to sleep with a nasal cannula, chest straps, and sensors.
Sleepiz aims to make this process easier and more convenient for everyone involved. Sleepiz leverages the power of sleep insights with a device that is simply placed next to the bed. The Sleepiz One operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical grade accuracy. While currently a screening method, in the near future, it is intended to be a tool for diagnosis.
Why LuftiBus from LUNGE ZÜRICH?
LUNGE ZÜRICH is the contact for all questions regarding lungs, lung health, air as well as breathing - and therefore the perfect partner for the start-up Sleepiz. It is one of the 19 cantonal lung leagues in Switzerland and belongs to the umbrella organization Lungenliga Schweiz. LUNGE ZÜRICH supports over 15 000 people with lung disease in the canton of Zurich with counselling and care services.
With the LuftiBus, LUNGE ZÜRICH makes an important contribution to prevention and early detection of respiratory diseases. LuftiBus’ experts conduct on-site pulmonary function tests and with the help of Sleepiz, now also sleep screenings. They provide information about the importance of healthy lungs, clean air, and lung diseases. The LuftiBus and Sleepiz sleep screenings can be booked for groups of at least 10 individuals. You can find all information about the offering HERE.
Sleepiz AG (Ltd.) is a Zürich based startup with a mission to provide patient-centric disease management through seamless integration of contactless monitoring into people’s homes. Sleepiz leverages the power of sleep insights with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical grade accuracy.
While currently focusing on respiratory illnesses, Sleepiz aims to improve people’s lives by creating the future of healthcare. By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence, in the future Sleepiz will not only be able to diagnose sleep disorders but also perform long-term monitoring. Thereby, the progression of chronic diseases will be monitored to allow faster intervention and better treatment.